



HHS Public Access

Author manuscript

JAMA Neurol. Author manuscript; available in PMC 2016 September 03.

Published in final edited form as:

JAMA Neurol. 2015 September ; 72(9): 1043–1051. doi:10.1001/jamaneurol.2015.1424.

Genetic Modifiers of Age at Onset in Carriers of the G206A Mutation in *PSEN1* With Familial Alzheimer Disease Among Caribbean Hispanics

Joseph H. Lee, DrPH, Rong Cheng, PhD, Badri Vardarajan, PhD, Rafael Lantigua, MD, Dolly Reyes-Dumeyer, BS, Ward Ortmann, PhD, Robert R. Graham, PhD, Tushar Bhangale, PhD, Timothy W. Behrens, MD, Martin Medrano, MD, Ivonne Z. Jiménez-Velázquez, MD, and Richard Mayeux, MD, MSc

The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York (Lee, Cheng, Vardarajan, Lantigua, Reyes-Dumeyer, Mayeux); Gertrude H. Sergievsky Center, Columbia University, New York, New York (Lee, Cheng, Vardarajan, Mayeux); Department of Epidemiology, School of Public Health, Columbia University, New York, New York (Lee, Mayeux); Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York (Lantigua, Behrens); Genentech, South San Francisco, California (Ortmann, Graham, Bhangale); School of Medicine, Pontificia Universidad Católica Madre y Maestra, Santiago, Dominican Republic (Medrano); Department of Internal Medicine, University of Puerto Rico School of Medicine, San Juan, Puerto Rico (Jiménez-Velázquez); Department of Psychiatry, Columbia University, New York, New York (Mayeux); Department of Neurology, Columbia University, New York, New York (Mayeux)

Abstract

Importance—The present study identified potential genetic modifiers that may delay or accelerate age at onset of familial Alzheimer disease (AD) by examining age at onset in *PSEN1*

Corresponding Author: Joseph H. Lee, DrPH, Gertrude H. Sergievsky Center, Columbia University, 630 W 168th St, P&S Unit 16, New York, NY 10032 (JHL2@columbia.edu).
Drs Lee and Cheng contributed equally.

Author Contributions: Drs Lee and Mayeux had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Lee, Cheng, Mayeux.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Lee, Mayeux.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Lee, Cheng, Vardarajan, Bhangale.

Obtained funding: Mayeux.

Administrative, technical, or material support: Lee, Lantigua, Reyes-Dumeyer, Ortmann, Behrens, Medrano, Jiménez-Velázquez, Mayeux.

Study supervision: Lee, Mayeux.

Supplemental content at jamaneurology.com

Conflict of Interest Disclosures: Drs Ortmann, Graham, Bhangale, and Behrens reported being full-time employees of Genentech, Inc. No other disclosures were reported.

Additional Contributions: Jessica Russo, BA, provided thorough examination of the candidate genes. The Columbia University team performed analyses of genotype-phenotype relations in the *PSEN1* p.G206A carrier families and the GWAS of LOAD. Ms Russo was compensated for her work.

mutation carrier families, and further investigation of these modifiers may provide insight into the pathobiology of AD and potential therapeutic measures.

Objective—To identify genetic variants that modify age at onset of AD.

Design, Setting, And Participants—Using a subset of Caribbean Hispanic families that carry the *PSEN1* p.G206A mutation, we performed a 2-stage genome study. The mutation carrier families from an ongoing genetic study served as a discovery set, and the cohort of those with LOAD served as a confirmation set. To identify candidate loci, we performed linkage analysis using 5 p.G206A carrier families (n = 56), and we also performed whole-exome association analysis using 31 p.G206A carriers from 26 families. To confirm the genetic modifiers identified from the p.G206A carrier families, we analyzed the GWAS data for 2888 elderly individuals with LOAD. All study participants were Caribbean Hispanics.

Main Outcomes and Measures—Age at onset of AD.

Results—Linkage analysis of AD identified the strongest linkage support at 4q35 (LOD [logarithm of odds] score, 3.69), and the GWAS of age at onset identified variants on 1p13.1, 2q13, 4q25, and 17p11. In the confirmation stage, genewise analysis identified *SNX25*, *PDLIM3*, and 3 SH3 domain genes (*SORBS2*, *SH3RF3*, and *NPHP1*) to be significantly associated with LOAD. Subsequent allelic association analysis confirmed *SNX25*, *PDLIM3*, and *SORBS2* as genetic modifiers of age at onset of EOAD and LOAD and provided modest support for *SH3RF3* and *NPHP1*.

Conclusions and Relevance—Our 2-stage analysis revealed that *SNX25*, *PDLIM3*, and *SORBS2* may serve as genetic modifiers of age at onset in both EOAD and LOAD.

In 2001, we identified a p.*Gly206Ala* (g.44636G>C) variant in *PSEN1* (OMIM 104311) in members of 8 Caribbean Hispanic families with early-onset Alzheimer disease (EOAD) from Puerto Rico.¹ Subsequently, Arnold and colleagues² also reported this mutation in additional individuals from Puerto Rico but not in other ethnic groups. The mean age at onset among mutation carriers was 55.6 years but was highly variable within families, ranging from 22 to 77 years. The presence of neither an *APOE* ε4 allele nor any antecedent environmental, health-related, or social factors could explain the differences in the age at onset among mutation carriers, leading us to suspect that other genes were involved in determining when, but not whether, p.G206A carriers develop AD.

Late-onset diseases, including AD,^{3,4} Huntington disease,⁵⁻⁷ and Parkinson disease,^{8,9} have been studied for genetic modifiers of age at onset in the presence of a major genetic risk factor (ie, pathogenic mutation), recognizing that there are likely genetic variants that contribute to phenotypic expression. Few studies^{10,11} have reported gene-gene interaction in AD because different individuals are likely to carry different genetic risk factors. Since there are approximately 185 known *PSEN1* variants associated with AD and these variants are rare, most studies will not have sufficient statistical power.¹²

We conducted a 2-stage study on a set of families multiply affected by AD with at least one carrier of the p.G206A variant in the *PSEN1* gene to identify genetic modifiers of age at onset among carriers. In the discovery stage, we used these genetically homogeneous families in which nearly all carriers of the *PSEN1* mutation had p.G206A. Using a subset of

carrier family members, we applied both genome-wide linkage and exome sequencing analyses (eFigure 1 in the Supplement). In the confirmation stage, we examined allelic association between age at onset and variants in the same candidate genes in a cohort of the same ancestry with late-onset AD (LOAD). We report that variants in *SNX25*, *PDLIM3*, *SORBS2*, and *SH3RF3* were associated with variation in age at onset in families with a copy of *PSEN1* p.G206A mutation and in LOAD. In addition, at least one variant in *NPHP1* was associated with variation in age at onset of AD.

Methods

Discovery Cohort

We conducted a 2-stage study to identify genetic modifiers of age at onset of AD using multiple sets of data in which some were family based and others comprised unrelated individuals (eFigure 1 in the Supplement). The study protocol was approved by the Columbia University Institutional Review Board, and written informed consent was provided by all the participants. Using 56 family members from 5 families with EOAD with the *PSEN1* p.G206A mutation, we performed linkage analysis to identify candidate loci. These families represent a subset of *PSEN1* carrier families with a wide range of age at onset among affected individuals. Family members resided in the United States, Puerto Rico, Dominican Republic, and countries in South America. Although these families were selected because multiple members had EOAD (age at onset, 65 years), many of these families had some family members who had LOAD (age at onset, >65 years). In addition, we performed an exome sequencing experiment and found 31 carriers from 26 families who had multiple affected members and at least 2 who had the *PSEN1* p.G206A mutation. Nine of the 31 individuals were also included in the linkage analysis. Given the small sample size of carrier families examined, the main goal of this discovery stage is to prioritize candidate loci.¹³

Confirmation Cohort

For the LOAD validation experiment, we examined 2888 Caribbean Hispanic elderly people who were noncarriers of the *PSEN1* p.G206A mutation and were included in separate genome-wide association studies (GWAS) (eTable 1 in the Supplement).

Genetic Analysis

All persons were genotyped using the 6K Illumina linkage panel single-nucleotide polymorphism (SNP) chips (Illumina Inc). This SNP chip was designed to obtain information for linkage signals. Before analysis, we conducted the standard quality control checks, including checking of the reported family relationships using the software PREST,¹⁴ Hardy-Weinberg equilibrium, and genotyping rate. The details of the quality control procedures are presented elsewhere.^{15,16}

Genome-wide Linkage Analysis

To identify regions that may contain variants that could modify age at onset, linkage analyses were performed using the 6K linkage panel SNP data from 56 individuals in 5 families. We examined AD and age at onset as phenotypes. We reasoned that variants that lead to early age at onset are likely to increase the risk of AD, whereas variants that delay

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

age at onset may reduce the risk. For AD phenotype, single-point analysis assumed an autosomal dominant mode of inheritance and used the affecteds-only approach¹⁷ in PSEUDOMARKER.¹⁸ For age-at-onset phenotype, we used age at onset for affected individuals and age at last examination for unaffected individuals. We then applied the multipoint variance component method to identify candidate loci as implemented in SOLAR statistical software.¹⁹ This variance component model was adjusted for sex, *APOE* ε4, and AD status.

To prioritize candidate genes under the linkage peak at 4q35.1, the top linkage peak, we screened candidate genes using CANDID, version 1.1.²⁰ Higher weights were given to logarithm of odds (LOD) score (weight, 2) and conservation (weight, 2) compared with literature (which included the keywords *Alzheimer disease*, *neurodegeneration*, *early onset*, and *beta amyloid*) (weight, 1) and gene expression (weight, 1).

Exome Sequencing

Whole-exome capture libraries were constructed from DNA from whole blood of the samples after sample shearing, end repair, phosphorylation, and ligation to bar-coded sequencing adaptors (eFigure 2 in the Supplement). The ligated DNA was subjected to exonic hybrid capture using the Nimble exome capture array (<http://www.nimblegen.com/seqcapez/>). Samples were multiplexed and sequenced on multiple Illumina HiSeq flow cells for a mean target exome coverage of 80× to generate paired-end reads of 90 base pairs.

Read Mapping, Variant Calling, and Downstream Bioinformatics Analyses

Prealignment quality control of the read data to identify failed runs and lanes was performed using the R BioConductor package: ShortRead (<http://www.bioconductor.org/>). Sequence alignment was performed using the aligner BWA. Polymerase chain reaction duplicates (reads) were removed using Picard tools. Base quality recalibration and realignment around indels were performed using the Genome Analysis Toolkit (<https://www.broadinstitute.org/gatk/>). Multisample variant calling and quality control of the call were then performed using the Genome Analysis Toolkit. On the basis of the hypothesis that the mutation underlying this rarer form of EOAD was not present in the general population, SNPs identified in the 1000 Human Genomes (HG) project (version 2010-11; <http://www.1000genomes.org>) or in dbSNP (build 134; <http://www.ncbi.nlm.nih.gov/projects/SNP>) were removed. Exonic coding variants were identified and annotated by ANNOVAR (<http://annovar.openbioinformatics.org/en/latest/>). Non-exonic and synonymous variants were filtered from the variant list using predictions from SIFT (Sorting Intolerant From Tolerant) software, version 4.0 (<http://sift.jcvi.org>).

Genome-wide Association Analysis

Using 31 individuals with exome sequencing data, we examined candidate genes under the top linkage peak and the rest of the exome by applying a mixed linear model adjusting for sex, *APOE* genotype, affection status, and kinship coefficient. The kinship coefficient matrix using the R functions²¹ was included in the model to take into account relatedness among family members.

Replication Using the LOAD Hispanic GWAS Data Set: Genewise Analysis

To determine whether candidate genes identified from the EOAD cohort were similarly associated with age at onset of AD in the LOAD cohort of the same ethnic background, we performed gene wise association analysis using family-based SKAT software (FAMSKAT),²² adjusting for sex, AD status, and *APOE* ε4. This approach was necessary because (1) multiple variants within one gene had modest effects on age at onset and (2) most of the variants identified from exome sequencing were absent in the GWAS data of Caribbean Hispanics.

Imputation of the LOAD Hispanic GWAS Data Set

Imputations of 5 genes (*SNX25*, *PDLIM3*, *SORBS2*, *SH3RF3*, *NPHP1*) were performed based on cosmopolitan phased haplotypes of 1000 HG, version 2010–11 (data freeze, 2012-03-04 haplotypes; <http://csg.sph.umich.edu//abecasis/MaCH/download/1000G.2012-03-14.html>). PLINK, version 1.07 (<http://pngu.mgh.harvard.edu/~purcell/plink/>) was used for imputation. Before imputing, a number of filters were implemented in the Hispanic GWAS genotypic data by removing markers that had a minor allele frequency less than 1%, a Hardy-Weinberg equilibrium $P < 10^{-6}$, Hispanic GWAS SNP alleles mismatched with those of 1000 HG project and not present in the 1000 HG panel, and flipping of any SNP when appropriate to the forward strand. A total of 348 924 SNPs for 2 regions of chromosome 2 (175 288 SNPs, approximately 14 Mbp) and chromosome 4 (173 636 SNPs, approximately 10 Mbp) were imputed. For single-variant and single-trait association with imputed genotypes, 2 additional filters were implemented: minor allele frequency greater than 1% and an information score greater than 0.8 (a quality score from the imputation), which reduced the analysis to 2636 variants within the 3 genes.

Association Analysis and Meta-analysis

We applied the same multivariate linear mixed model that adjusted for sex, AD status, and *APOE* ε4²¹ as above to test the allelic association between age at onset and variants in LOAD. We then conducted a meta-analysis to assess whether the SNPs in the 3 candidate genes were significantly associated with the LOAD GWAS data sets. For this purpose, we estimated the meta-analysis of P values from 4 studies as implemented in the METAL (<http://csg.sph.umich.edu//abecasis/metal/>), which estimates a single summary P value across 3 data sets. An overall z statistic and P value were calculated while taking into account the number of individuals examined in each study.

Results

Study Participants

Table 1 details the 3 sets of Caribbean Hispanics investigated: (1) families who have multiple affected members and at least one carrying the *PSEN1* p.G206A mutation were analyzed using linkage analysis; (2) carriers of the *PSEN1* p.G206A mutation from families who have multiple affected members were analyzed using exome sequencing; and (3) 3 confirmatory GWAS data sets of Caribbean Hispanics primarily composed of LOAD were studied,^{15,23} which were analyzed using a linear mixed model to assess allelic association.

All 3 data sets had both family members and unrelated individuals, and appropriate statistical methods were applied to account for nonindependence.

Linkage Analysis Set—Of 56 family members included in the linkage analysis, 21 (37.5%) were affected, and 32 (57.1%) were unaffected. A total of 37 (66.1%) of the family members were women, the mean (SD) age at onset of AD was 57.2 (7.0) years (range, 43.0-73.0 years), and the mean educational level was 10.0 years. The overall allele frequency of *APOE* ε4 was 20.5%.

Exome Sequencing Set—Of 31 *PSEN1* p.G206A mutation carriers from 26 families who were included in the exome sequencing experiment, 26 (83.9%) of the mutation carriers had been clinically diagnosed as having AD. The other persons were unaffected carriers. Nineteen participants (61.3%) were women, the mean (SD) age was 57.9 (9.9) years (range, 44.0-77.0 years), and the mean educational level was 9.1 years. Most mutation carriers reported Puerto Rico as the country of origin, whereas the others were from the Dominican Republic.

Caribbean Hispanic GWAS Set—Among 2888 individuals in the confirmation set, 1473 (51.0%) of the individuals were affected with AD, and 1918 (66.4%) were women. Most affected individuals had LOAD, and their mean age at onset was 74.0 years (range, 30.0-105.0 years). The proportion of *APOE* ε4 carriers (23.0%) was comparable to those with EOAD family members.

Genome-wide Linkage Analysis of Families Carrying the *PSEN1* p.G206A Mutation

For the purpose of gene discovery, we conducted genome-wide linkage analyses of AD and age at onset using 5 multiplex families with variable age at onset. The linkage analysis of AD identified the strongest linkage support for rs13478 at 4q35.1 (LOD score, 3.69), and 3 additional SNPs (rs1024026, rs1983503, rs2036912) from the 6K linkage panel were suggestive (Figure). This locus included multiple genes in linkage disequilibrium, including *C4orf41*, *STOX2*, *MLF1IP*, *SORBS2*, and *FAM149A*. Our subsequent informatics analysis based on the CANDID algorithm²⁰ identified 3 top candidate genes: *SLC25A4*, *SORBS2*, and *KIAA1430*. On the other hand, the linkage analysis of age at onset that adjusted for sex, AD status, and *APOE* ε4 did not identify any SNPs with suggestive or significant LOD scores. An additional model that included the presence or absence of the *PSEN1* p.G206A variant in addition to sex, AD status, and *APOE* ε4 yielded the highest LOD score of 0.75.

Targeted and Genome-wide Association Analysis of *PSEN1* p.G206A Carriers

Using 31 *PSEN1* p.G206A mutation carriers, we performed targeted association analysis with the genes located under the linkage peak at 4q35.1. In addition, we performed genome-wide association analysis of age at onset in the rest of the exome by applying a multivariate linear mixed model that adjusted for sex, AD status, *APOE* ε4, and kinship coefficient.²¹ The linear mixed model was applied to take into account 5 individuals who were related to others included in the exome sequencing experiment. Under the linkage peak, several SNPs provided modest support for association with age at onset, but we focused on *SORBS2* because of the strong support from the informatics analysis and the linkage analysis. The

effect of the minor allele of rs13130022 in *SORBS2* was associated with a delay in age at onset by 11.1 years (see β coefficients in Table 2). In the remaining exome, the strongest signal for age at onset was observed at rs906815 in *NPHP1* at 2q13 ($P = 4.51 \times 10^{-6}$).

Specifically, individuals carrying the rare A allele for rs906815 had an age at onset approximately 11.7 years earlier for having one copy of the A allele compared with those who do not, thereby leading to nearly a difference of 2 decades in age at onset (ie, 44 vs 64.17). In addition, the effect variants in *SNX25* and *SH3RF3* were associated with a delay in age at onset by 8.8 and 9.3 years, respectively, whereas the effect variant in *PDLIM3* was associated with an earlier onset by 12 years. In addition, rs696662 on 1p13.1 ($P = 6.8 \times 10^{-6}$), rs906815 on 2q13 ($P = 4.5 \times 10^{-6}$), and rs3026115 on 17p13.2 ($P = 7.8 \times 10^{-5}$) had SNPs with strong support for allelic association.

To be conservative, we performed one additional analysis of age at onset of AD in which we restricted the analysis to affected individuals only. This analysis yielded comparable results as the survival analysis approach. For example, rs906815 in *NPHP1* had a P value of 4.13×10^{-6} , and other SNPs that were significant in the earlier analysis remained statistically significant, but the P values were somewhat weakened (eTable 2 in the Supplement).

Replication in Individuals With LOAD: Genewise Analysis

To determine whether the variants discovered from the *PSEN1* p.G206A carrier families were likely to be associated with variation in age at onset in LOAD, we first conducted genewise association analysis using FAMSKAT²² because the Hispanic GWAS data sets did not include the variants identified from exome sequencing of the discovery set. We confirmed that *SNX25* ($P = 1.26 \times 10^{-15}$), *PDLIM3* ($P = 1.17 \times 10^{-11}$), *SORBS2* ($P = 3.8 \times 10^{-6}$), *NPHP1* ($P = 5.47 \times 10^{-5}$), and *SH3RF3* ($P = 2.7 \times 10^{-11}$) were associated with age at onset in Caribbean Hispanics with LOAD, further supporting that these genes may be involved functionally in altering phenotypic expression in AD.

Replication in Individuals With LOAD: SNP-wise Analysis

To further explore whether allelic association persists within those candidate genes in LOAD, we examined SNPs from the 3 GWAS data sets of Caribbean Hispanic ancestry, focusing on the SNPs in the same linkage disequilibrium block as the original discovery variants. Because the GWAS data sets did not have genotypes for many of the variants discovered from exome sequencing, we performed imputation using PLINK²⁴ and then used both genotype and imputed SNPs for allelic association. We limited the use of imputed SNPs to those with an information score greater than 0.8 by PLINK analysis. As shown in eFigure 3 in the Supplement, pairwise D' values across the chromosomal regions encompassing the discovery variants in candidate loci were high and were comparable across the 3 GWAS data sets.

Table 3 indicates that multiple genotyped or imputed data in the candidate genes were associated with age at onset in LOAD. In this confirmation analysis, 14 SNPs in *SNX25* were associated with age at onset at $P < .05$, and variants were associated with 1 to 6 years of difference in age at onset in LOAD. For *PDLIM3*, 3 SNPs were associated with variation in age at onset and were associated with a difference of 2.6 to 3.6 years in mean age at onset.

For *SORBS2*, 11 of 1246 SNPs or indels flanking the original discovery variant were significantly associated with age at onset of LOAD at $P < .05$, and the variants were associated with 1 to 4.6 years of mean age difference in onset. It is of interest to note that, for *SORBS2*, the same allele was associated with age at onset in all 3 GWAS data sets, and the allele frequency for the associated SNP was consistent across data sets, ranging from 0.032 to 0.222 with a median of 0.194. For *SH3RF3*, 5 SNPs were associated with age at onset at $P < .05$ in LOAD, and the difference in mean age at onset ranged from 1 to 2.9 years. For *NPHP1*, only one SNP was associated with age at onset.

Table 4 summarizes reanalysis of the 10 SNPs from the 2 candidate genes (*SORBS2* and *SH3RF3*) using genotyped data. The rationale for genotyping these subsets of SNPs from Table 3 was that the information score for the imputed SNPs in those 2 genes did not reach the satisfactory quality control threshold of 0.8 according to our PLINK analysis; thus, the results from the meta-analysis based on smaller data sets are likely to be less reliable when compared with other SNPs with high information scores. When genotyped data were used, rs72939527 in *SH3RF3* had the strongest support for allelic association ($P = .007$). The T allele in rs72939527 was associated with a 2.7-year earlier age at onset compared with the reference allele, whereas other variants did not reach statistical significance ($P = .22-.47$).

Discussion

We focused on founder mutation *PSEN1* p.G206A with high penetrance to identify genetic modifiers of age at onset of EOAD and LOAD and report that variants in *SNX25*, *PDLIM3*, *SORBS2*, *SH3RF3*, and *NPHP1* may contribute to variation in age at onset in EOAD and LOAD. This study of a founder mutation allows identification of a second locus that may alter the effect of the highly penetrant, nonsynonymous *PSEN1* p.G206A variant. This approach overcomes some of the limitations that are common in studies that examine gene-gene interaction in variants with modest to weak effect sizes. Furthermore, changes in age at onset by genotype among *PSEN1* p.G206A carrier families ranged from 10 to 20 years, whereas those among individuals with LOAD ranged from 1 to 6.2 years. This finding suggests that the difference in age at onset by genotype is likely to be smaller in noncarriers compared with G206A carriers.

Familial EOAD is caused by mutations in 3 genes: *APP*, *PSEN1*, and *PSEN2*.²⁵⁻²⁸ Support clearly exists for genetic modifiers because age at onset varies widely for carriers of *APP*, *PSEN2*, and *PSEN1*. To date, only a few studies^{3,4,11} have reported modifiers. Investigators have attributed observed variable age at onset in *PSEN2* to the *APOE* ε4 allele.^{3,4} For *PSEN1*, Vélez and colleagues¹¹ conducted a pooling- and bootstrap-based GWAS to identify multiple modifiers. Among those, they observed that rs10173717 in *NPHP1* may alter age at onset in *PSEN1* p.Glu280Ala carriers. However, rs10173717 reported by Vélez et al¹¹ was located 40.5 kilobases (kb) away from our own discovery signal rs906815 and 76.1 kb away from our GWAS signal rs17842680. The authors did not report the difference in age at onset by genotype.

In this study, 5 promising genetic modifiers were identified among families multiply affected by AD: *SNX25*, *PDLIM3*, *SORBS2*, *SH3RF3*, and *NPHP1*. *SNX25* has been implicated in

regulating endosome sorting and signaling.^{29,30} Given its potential role in regulating membrane protein trafficking excess levels of amyloid β in individuals with the *PSEN1* p.G206A variant, this gene may be a biologically relevant modifier. This hypothesis is further supported by an earlier report³¹ that found that *SNX3*, a gene in the same family, was associated with AD, and *SNX3* regulates and interacts with the retromer membrane. *PDLIM3* is reported to be associated with diabetes and cardiomyopathy.³² Although there have been reports of insulin-related genes, little is known about the role of *PDLIM3* in dementia to date. Interestingly, however, the PDZ domain is regulated by *SNX27* retromer protein, and deficiencies in retromers have been associated with AD.³³

The remaining 3 candidate genes encode proteins with a functional domain, SH3. These evolutionarily conserved domains are defined by sequence homology and are involved in protein-protein interaction.^{34,35} SH3 domains are ubiquitous intracellular protein modules; structural and functional studies³⁴⁻³⁷ reveal how they interact with their praline-rich ligands to promote the formation of specific protein aggregates. The SH3 domain is related to the WW and PTB domains³⁷ and may interact with *APP* to modulate the degradation of *APP*.³⁵ The *SORBS2* gene—an SH3-binding domain gene located in 4q35.1 under the strongest linkage peak—transcribes a brain-specific splice variant known as nARGBP2.³⁸ This variant was reported to influence the integrity of actin in the dendritic spines of neurons. Cestra and colleagues³⁹ observed that overexpression of nARGBP2 in mice caused aggregation of f-actin bundles in dendritic spines and may influence phenotypic expression. Because alteration of synaptic shape may be associated with the biological progression of AD, variants in *SORBS2* may influence variation in age at onset by affecting dendritic spine morphologic and subsequent neurodegenerative processes.

SH3RF3 is an important paralog of *SORBS2*. Because paralogs arise from gene duplication within the same species and we found allelic association between age at onset and *SORBS2* as well as *SH3RF3*, *SH3RF3* is a biologically plausible gene. In the present data set, the rare homozygous genotype carriers had age at onset approximately 20 years earlier than those with the wild-type homozygous genotype under the model that adjusted for sex, AD, *APOE* ε4, and kinship coefficient. These results suggest that some individuals harbor a variant in *SH3RF3* that may modify the effect of the *PSEN1* p.G206A mutation on the disease phenotype. We note that the SH3 domain is found in proteins of signaling pathways regulating the cytoskeleton. They also regulate the activity state of adaptor proteins (which mediate specific protein-protein interactions that drive the formation of protein complexes) and other tyrosine kinases (which transfer a phosphate group from adenosine tri-phosphate to a protein in a cell, thereby functioning as an on-and-off switch). Thus, it is plausible that this gene may be involved in variable gene expression of related genes, which in turn modify the age at onset of disease.

NPHP1, another SH3 domain gene, encodes a nephrocystin-1 protein that may influence cell division and cell signaling localized to microtubule-based structures.⁴⁰ This gene has been reported to be associated with retinitis pigmentosa, nephronophthisis, and neurodegeneration with brain iron accumulation 1. This disease is associated with dementia as part of the phenotypic spectrum, supporting biological relevance of this gene in the neurodegenerative process.

This study has some limitations. Age at onset of AD phenotype is inherently difficult to measure accurately because it is difficult to detect prodromal symptoms unless each individual is followed up longitudinally from preclinical stage to development of AD using sensitive biomarkers. Thus, reported age at onset is an approximation. In addition, the genetic variants identified from this study may be relatively common in Caribbean Hispanics but not in the general US populations. Thus, the identified variants themselves may have limited value in other ethnic cohorts. However, our earlier studies⁴¹⁻⁴³ have found that when 2 cohorts of different ethnicity are studied, the same set of genes tends to be implicated, but the effect size associated with each variant differs somewhat. For example, the effect size for each SNP vary among Caribbean Hispanics, African Americans, and whites^{41,42}; however, all 3 ethnic groups had SNPs that were significantly associated with AD within the gene. Similarly, SNPs in *ABCA7* were associated with AD in African Americans and whites, but the effect sizes differed.⁴³

Conclusions

This study of carriers of the *PSEN1* p.*G206A* mutation has identified variants in *SNX25*, *PDLIM3*, and a family of SH3 domain genes (*SORBS2*, *SH3RF3*, *NPHP1*) that may modify age at onset of EOAD. Furthermore, variants in *SORBS2* consistently were associated with delayed onset in EOAD and LOAD, although less profoundly so in LOAD. On the other hand, the discovery variant and flanking variants in *SH3RF3* and *NPHP1* were significantly associated with EOAD, but their effect size was modest with LOAD. One possible explanation for lack of association in the present data set may be that the effect size for *SH3RF3* and *NPHP1* may be relatively modest, and a larger study may be needed to detect significant association. The present findings are worthy of further investigation to understand the pathobiology of AD.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding/Support: This work was supported by grants R37-AG15473, P50-AG08702, and R01AG037212 from the National Institute on Aging, National Institutes of Health and grant R01-MH084995 from the National Institute of Mental Health.

Role of the Funder/Sponsor: Genentech contributed to the design, acquisition of sequencing and GWAS data, bioinformatics analysis of the sequence data, and review of the manuscript but did not play a role in management of the data, statistical genetics analysis, approval of the manuscript, and decision to submit the manuscript for publication.

References

1. Athan ES, Williamson J, Ciappa A, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. *JAMA*. 2001; 286(18):2257–2263. [PubMed: 11710891]
2. Arnold SE, Vega IE, Karlawish JH, et al. Frequency and clinicopathological characteristics of presenilin 1 Gly206Ala mutation in Puerto Rican Hispanics with dementia. *J Alzheimers Dis*. 2013; 33(4):1089–1095.

3. Marchani EE, Bird TD, Steinbart EJ, et al. Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset *PSEN2* families. *Am J Med Genet B Neuropsychiatr Genet*. 2010; 153B(5):1031–1041. [PubMed: 20333730]
4. Wijsman EM, Daw EW, Yu X, et al. *APOE* and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. *Am J Med Genet B Neuropsychiatr Genet*. 2005; 132B(1):14–20. [PubMed: 15389756]
5. Metzger S, Walter C, Riess O, et al. REGISTRY Investigators of the European Huntington's Disease Network. The V471A polymorphism in autophagy-related gene *ATG7* modifies age at onset specifically in Italian Huntington disease patients. *PLoS One*. 2013; 8(7):e68951. [PubMed: 23894380]
6. Farrow M, Chua P, Churchyard A, Bradshaw JL, Chiu E, Georgiou-Karistianis N. Proximity to clinical onset influences motor and cognitive performance in presymptomatic Huntington disease gene carriers. *Cogn Behav Neurol*. 2006; 19(4):208–216. [PubMed: 17159618]
7. Djoussé L, Knowlton B, Hayden MR, et al. Evidence for a modifier of onset age in Huntington disease linked to the *HD* gene in 4p16. *Neurogenetics*. 2004; 5(2):109–114. [PubMed: 15029481]
8. Thobois S, Ribeiro MJ, Lohmann E, et al. French Parkinson's Disease Genetics Study Group. Young-onset Parkinson disease with and without parkin gene mutations. *Arch Neurol*. 2003; 60(5): 713–718. [PubMed: 12756135]
9. Foroud T, Uniacke SK, Liu L, et al. Parkinson Study Group. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. *Neurology*. 2003; 60(5):796–801. [PubMed: 12629236]
10. Lalli MA, Garcia G, Madrigal L, et al. Exploratory data from complete genomes of familial Alzheimer disease age-at-onset outliers. *Hum Mutat*. 2012; 33(12):1630–1634. [PubMed: 22829467]
11. Vélez JI, Chandrasekharappa SC, Henao E, et al. Pooling/bootstrap-based GWAS (*pb*GWAS) identifies new loci modifying the age of onset in *PSEN1* p.Glu280Ala Alzheimer's disease. *Mol Psychiatry*. 2013; 18(5):568–575. [PubMed: 22710270]
12. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. *Hum Mutat*. 2012; 33(9):1340–1344. [PubMed: 22581678]
13. Terwilliger JD. On the resolution and feasibility of genome scanning approaches. *Adv Genet*. 2001; 42:351–391. [PubMed: 11037331]
14. Sun L, Wilder K, McPeek MS. Enhanced pedigree error detection. *Hum Hered*. 2002; 54(2):99–110. [PubMed: 12566741]
15. Lee JH, Cheng R, Barral S, et al. Identification of novel loci for Alzheimer disease and replication of *CLU*, *PICALM*, and *BIN1* in Caribbean Hispanic individuals. *Arch Neurol*. 2011; 68(3):320–328. [PubMed: 21059989]
16. Wijsman EM, Pankratz ND, Choi Y, et al. NIA-LOAD/NCRAD Family Study Group. Genome-wide association of familial late-onset Alzheimer's disease replicates *BIN1* and *CLU* and nominates *CUGBP2* in interaction with *APOE*. *PLoS Genet*. 2011; 7(2):e1001308. [PubMed: 21379329]
17. Knapp M. Alternative test for linkage between two loci. *Genet Epidemiol*. 1998; 15(5):511. [PubMed: 9728892]
18. Hiekkalinna T, Schäffer AA, Lambert B, Norrgrann P, Göring HH, Terwilliger JD. PSEUDOMARKER: a powerful program for joint linkage and/or linkage disequilibrium analysis on mixtures of singletons and related individuals. *Hum Hered*. 2011; 71(4):256–266. [PubMed: 21811076]
19. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet*. 1998; 62(5):1198–1211. [PubMed: 9545414]
20. Hutz JE, Kraja AT, McLeod HL, Province MA. CANDID: a flexible method for prioritizing candidate genes for complex human traits. *Genet Epidemiol*. 2008; 32(8):779–790. [PubMed: 18613097]
21. Therneau, T.; Atkinson, E.; Sinnwell, J.; Matsumoto, M.; Schaid, D.; McDonnell, S. [Accessed June 15, 2015] Package 'kinship2'. 2012. <http://cran.r-project.org/web/packages/kinship2/kinship2.pdf>

22. Chen H, Meigs JB, Dupuis J. Sequence kernel association test for quantitative traits in family samples. *Genet Epidemiol*. 2013; 37(2):196–204. [PubMed: 23280576]

23. National Center for Biotechnology Information. [Accessed 2014] dbGaR. 2014. <http://www.ncbi.nlm.nih.gov/>

24. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007; 81(3):559–575. [PubMed: 17701901]

25. St George-Hyslop PH, Petit A. Molecular biology and genetics of Alzheimer's disease. *C R Biol*. 2005; 328(2):119–130. [PubMed: 15770998]

26. Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer disease using molecular genetics. *JAMA*. 1997; 277(10):825–831. [PubMed: 9052714]

27. Schellenberg GD. Genetic dissection of Alzheimer disease, a heterogeneous disorder. *Proc Natl Acad Sci USA*. 1995; 92(19):8552–8559. [PubMed: 7567974]

28. Hardy J. The Alzheimer family of diseases. *Proc Natl Acad Sci USA*. 1997; 94(6):2095–2097. [PubMed: 9122152]

29. Wu J, Petralia RS, Kurushima H, et al. Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β -amyloid generation. *Cell*. 2011; 147(3):615–628. [PubMed: 22036569]

30. Wassmer T, Attar N, Harterink M, et al. The retromer coat complex coordinates endosomal sorting and dynein-mediated transport, with carrier recognition by the trans-Golgi network. *Dev Cell*. 2009; 17(1):110–122. [PubMed: 19619496]

31. Vardarajan BN, Bruesegem SY, Harbour ME, et al. Identification of Alzheimer disease-associated variants in genes that regulate retromer function. *Neurobiol Aging*. 2012; 33(9):2231.e15–2231.e30. [PubMed: 22673115]

32. Ohno, K.; Masuda, A. RNA pathologies in neurological disorders. In: Blass, JP., editor. *Neurochemical Mechanisms in Disease*. New York, NY: Springer Science and Business Media; 2011. p. 399-415.

33. Muhammad A, Flores I, Zhang H, et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and $\text{A}\beta$ accumulation. *Proc Natl Acad Sci U S A*. 2008; 105(20):7327–7332. [PubMed: 18480253]

34. Margolis B, Borg JP, Straight S, Meyer D. The function of PTB domain proteins. *Kidney Int*. 1999; 56(4):1230–1237. [PubMed: 10610414]

35. Sudol M. From Src homology domains to other signaling modules: proposal of the “protein recognition code”. *Oncogene*. 1998; 17(11 reviews):1469–1474. [PubMed: 9779993]

36. Morton CJ, Campbell ID. SH3 domains. *Curr Bbl*. 1994; 4(7):615–617.

37. Chen HI, Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. *Proc Natl Acad Sci USA*. 1995; 92(17):7819–7823. [PubMed: 7644498]

38. Hand D, Eiden LE. Human sorbin is generated via splicing of an alternative transcript from the *ArgBP2* gene locus. *Peptides*. 2005; 26(7):1278–1282. [PubMed: 15949647]

39. Cestra G, Toomre D, Chang S, De Camilli P. The Abl/Arg substrate ArgBP2/nArgBP2 coordinates the function of multiple regulatory mechanisms converging on the actin cytoskeleton. *Proc Natl Acad Sci USA*. 2005; 102(5):1731–1736. [PubMed: 15659545]

40. Mollet G, Silbermann F, Delous M, Salomon R, Antignac C, Saunier S. Characterization of the nephrocystin/nephrocystin-4 complex and subcellular localization of nephrocystin-4 to primary cilia and centrosomes. *Hum Mol Genet*. 2005; 14(5):645–656. [PubMed: 15661758]

41. Lee JH, Cheng R, Schupf N, et al. The association between genetic variants in *SORL1* and Alzheimer disease in an urban, multiethnic, community-based cohort. *Arch Neurol*. 2007; 64(4): 501–506. [PubMed: 17420311]

42. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat Genet*. 2007; 39(2):168–177. [PubMed: 17220890]

43. Reitz C, Jun G, Naj A, et al. Alzheimer Disease Genetics Consortium. Variants in the ATP-binding cassette transporter (*ABCA7*), apolipoprotein E $\epsilon 4$, and the risk of late-onset Alzheimer disease in African Americans. *JAMA*. 2013; 309(14):1483–1492. [PubMed: 23571587]




Figure. Results From Linkage and Association Analysis for 4q35

The bars represent logarithm of odds (LOD) scores from single-point linkage analysis, and points without the bar represent $-\log_{10} P$ values from association analysis. Approximate locations for relevant genes as well as physical locations on chromosome 4 (chr4) are presented at the bottom of the figure.

Table 1
Demographic and Clinical Characteristics of Sequenced Participants and Family Members^a

Characteristic	Genotyped (n = 56 [5 Families])	Sequenced (n = 31 [26 Families])	Combined GWAS (N = 2888)
Affection status			
Affected	21 (37.5)	26 (83.9)	1473 (51.0)
Unaffected	32 (57.1)	5 (16.1)	1408 (48.8)
Unknown	3 (5.4)	0	6 (0.2)
Sex, male:female	19:37 (33.9:66.1)	12:19 (38.7:61.3)	970:1918 (33.6:66.4)
Age at onset or age at last examination, mean (SD), y	57.2 (7.0)	57.9 (9.9)	74.0 (10.0)
Educational level, mean (SD), y	10.0 (4.6)	9.1 (5.2)	5.7 (4.7)
<i>APOE</i> frequency			
E4	23 (20.5)	19 (30.6)	1238 (23.0)
E3	85 (75.9)	43 (69.4)	3849 (71.5)
E2	4 (3.6)	0 (0.0)	293 (5.5)

Abbreviation: GWAS, genome-wide association study.

^aData are presented as number (percentage) of participants unless otherwise indicated. The combined GWAS data set has a total of 2324 unrelated individuals (2321 families and 3 individuals who married into the families).

Table 2
Summary of Linkage, Allelic, and Genewise Association Analyses in EOAD and LOAD

Gene	EOAD Exome Sequencing–Allelic Association			LOAD-GWAS		
	SNP	Location, bp	β	P Value	No. of SNPs ^a	P Value for Genewise Analysis
Linkage Signal						
4q35						
<i>STOX2</i>	rs28411264	184 908 447	.301	.03851	12	.83
<i>ENPP6</i>	rs13147555	185 074 686	−6.06	.03024	28	.002
<i>MLF1IP</i>	rs1401359	185 640 216	−5.11	.09064	58	7.22×10^{-6}
<i>SNX25</i>	rs11730401	186 268 129	8.75	.0004	17	1.26×10^{-5}
<i>PDLIM3</i>	rs28522047	186 446 018	−11.97	.1218	13	1.17×10^{-11}
<i>SORBS2</i>	rs13130022	186 678 161	11.11	.0013	143	3.80×10^{-6}
<i>FAM119A</i>	rs2276920	187 078 938	7.11	.01671	14	.04
Association Signal						
2q13						
<i>SH3RF3</i>	rs6542814	109 928 460	9.30	.001	157	2.70×10^{-11}
<i>NPHP1</i>	rs906815	110 942 496	−11.69	4.51×10^{-6}	12	5.47×10^{-5}

Abbreviations: bp, base pair; EOAD, early-onset Alzheimer disease; GWAS, genome-wide association study; LOAD, late-onset Alzheimer disease; SNP, single-nucleotide polymorphism.

^aThe SNP with the strongest P value from the exome sequencing experiment is given.

Table 3
Meta-analysis in Late-Onset Alzheimer Disease and the Difference in Mean Age at Onset by Genotype Among Caribbean Hispanics

SNP	Location, bp (HG19)	A1 ^a	A2 ^a	Freq ^a	z Score	P Value	Direction ^b	S1 ^c	S2 ^c	S3 ^c	Difference ^d
<i>SNX25(4q35)</i>											
rs72706074	186 135 900	G	A	0.072	2.07	.03821	+++	1	1	1	1.2
rs72706075	186 136 511	C	A	0.071	2.07	.03847	+++	1	1	1	1.0
rs111645866	186 137 102	A	C	0.071	2.07	.03847	+++	1	1	1	1.0
rs72708003	186 143 673	T	C	0.043	-2.40	.01634	---	1	1	1	-0.4
rs73873407	186 157 838	C	T	0.019	-2.25	.02472	---	1	1	1	-6.2
rs73873412	186 167 895	G	C	0.035	-2.42	.01538	?--	1	1	1	-2.1
rs73873414	186 169 190	C	A	0.035	-2.42	.01538	?--	1	1	1	-2.1
rs73873415	186 171 421	T	C	0.035	-2.42	.01538	?--	1	1	1	-2.2
rs73873416	186 174 202	G	A	0.034	-2.15	.03193	?--	1	1	1	-2.1
rs10028004	186 177 378	G	A	0.021	-2.06	.03991	--?	1	1	1	-1.9
rs114698167	186 188 966	A	C	0.048	2.09	.0368	?+?	1	1	1	1.8
rs72709980	186 207 628	A	T	0.034	2.50	.01242	?+?	1	1	1	2.8
rs140555723	186 241 606	G	A	0.042	2.54	.01122	+++	1	1	1	2.7
rs1288550	186 259 737	T	C	0.034	2.32	.02016	?+?	1	1	1	2.4
<i>PDLIM3(4q35)</i>											
rs1385580	186 414 852	C	T	0.036	-2.33	.02006	?-?	1	1	1	-3.4
rs143417134	186 415 740	T	C	0.010	-2.34	.01955	?-?	1	1	1	-3.6
rs79071575	186 442 445	T	C	0.027	-2.35	.01877	?-?	1	1	1	-2.6
<i>SORBS2(4q35)</i>											
rs146271237	186 662 630	C	T	0.043	-1.97	.04856	---	1	1	1	-4.6
rs10009206	186 663 793	C	T	0.144	-2.17	.02995	--?	G	G	G	-1.0
rs7679506	186 664 542	G	T	0.153	-2.55	.01084	---	G	G	G	-1.0
rs1039239	186 667 811	A	G	0.169	2.09	.03679	+++	1	1	1	0.2
rs13130022 ^e	186 678 161	C	T	0.213	1.90	.05763	+++	1	1	1	1.5
rs1021678	186 678 768	A	G	0.204	2.30	.02155	+++	1	1	1	1.6

SNP	Location, bp (HG19)	A1 ^a	A2 ^a	Freq1 ^a	z Score	P Value	Direction ^b	S1 ^c	S2 ^c	S3 ^c	Difference ^d
rs12715855	186 687 554	A	C	0.203	2.19	.02827	+++	1	1	1	1.6
186687667	186 687 667	TCA	T	0.204	2.30	.02155	+++	1	1	1	1.6
186687668	186 687 668	CACAT	C	0.203	2.44	.01451	+++	1	1	1	1.7
rs1039236	186 688 918	T	C	0.203	2.19	.02827	+++	1	1	1	1.6
rs1039235	186 690 013	A	T	0.203	2.44	.01451	+++	1	1	1	1.7
186691125	186 691 125	G	GC	0.202	2.34	.0193	+++	1	1	1	1.7
<i>SH3R73/2q13</i>											
rs72939527	109 917 895	T	C	0.012	2.18	.0295	?++	1	1	1	2.9
rs6542814 ^e	109 928 460			.001							1.1
rs11679797	109 973 646	G	T	0.026	1.99	.0462	?+?	1	1	1	1.1
rs13013000	109 982 224	T	G	0.034	2.16	.0307	?+?	1	1	1	0.8
rs11674377	109 984 093	A	G	0.034	2.16	.0307	?+?	1	1	1	1.1
rs113509962	109 987 615	T	C	0.011	-2.37	.0179	-??	1	1	1	...
<i>NPHP1/2q13</i>											
rs17842680	110 906 930	G	A	0.041	1.97	.04942	+++	1	1	1	0.9
rs906815 ^e	110 942 496	A	G	0.282	0.31	.7547	-++	1	G	G	-0.9

Abbreviations: A1, allele 1; A2, allele 2; bp, base pair; Freq1, frequency of allele 1; G, genotype; HG19, human genome assembly 19; I, imputed; S1, GWAS dataset 1; S2, GWAS dataset 2; S3, GWAS dataset 3; SNP, single-nucleotide polymorphism.

^aMinor allele and its frequency.

^bDirection of the β coefficient in 3 Hispanic genome-wide association data sets; plus sign indicates age at onset increases with dosage of allele; minus sign, age at onset decreases; and question mark, not computed because quality of imputation is poor.

^cI and G in each Hispanic genome-wide data set, where S1 represents dataset 1, S2, dataset 2, and S3 dataset 3. Imputed SNPs with an information score greater than 0.8 by PLINK analysis were used; otherwise, imputed SNPs were dropped, representing blank cells.

^dDifference in mean age by genotype. When available, mean ages at onset of 2 homozygotes were used to compute the difference in mean onset. When a homozygous rare variant was absent, mean age at onset of heterozygous genotype was used.

^eThe SNPs from the discovery.

Table 4
Reanalysis of *SH3RF3* and *SORBS2* in Late-Onset Alzheimer Disease Using Genotype Data and Difference in Age at Onset of Alzheimer Disease by Genotype

Chromosome	SNP	Location, bp (HG19)	A1	No. of Genotyped Persons	Age-at-Onset Phenotype			Alzheimer Disease Phenotype		
					β	Statistic	P Value	β	Statistic	P Value
<i>SH3RF3^a</i>										
2	rs72939527	109 917 895	T	1705	-2.863	-2.692	.007	1.123	2.624	.009
2	rs6542814	109 928 460	A	1697	0.374	1.231	.22	1.092	2.537	.01
2	rs11679797	109 973 646	G	1703	-1.007	-1.032	.30	1.091	2.543	.01
2	rs13013000	109 982 224	T	1697	-0.695	-0.729	.47	1.114	2.593	.01
2	rs11674377	109 984 093	A	1699	-1.037	-1.073	.28	1.100	2.559	.01
2	rs17842680	110 906 930	G	1700	0.686	1.054	.29	1.028	2.385	.02
2	rs906815	110 942 496	A	1702	-0.329	-1.015	.31	1.116	2.596	.01
<i>SORBS2</i>										
4	rs1009306	186 663 793	C	1700	0.103	0.244	.81	1.077	2.504	.01
4	rs1021678	186 678 768	A	1700	0.272	0.700	.48	1.111	2.583	.01
										.7

Abbreviations: A1, allele 1; bp, base pair; HG19, human genome assembly 19; SNP, single-nucleotide polymorphism.

^ars113309962 (109987615bp) was homozygous.